10:44 AM EST, 11/10/2025 (MT Newswires) -- InflaRx ( IFRX ) said Monday that a phase 2a study evaluating INF904 in hidradenitis suppurative, or HS, and chronic spontaneous urticaria, or CSU, demonstrated improvements in clinical endpoints, supporting its further development in both indications.

Clinical endpoints for HS include reduction in abscesses and nodules, and draining tunnels, which the product candidate achieved, InflaRx ( IFRX ) said. In CSU, InflaRx ( IFRX ) said it observed "substantial" reductions in patients' seven-day Urticaria Activity Score, among other endpoints.

The company said it intends to complete the four-week post-treatment observation period under the phase 2a study and plans to advance clinical development to a phase 2b trial in 2026.

Shares of InflaRx ( IFRX ) were up more than 26% in recent Monday trading.

Price: 1.56, Change: +0.33, Percent Change: +26.83